Compound ID | 493
ELB-21
Class: DNA synthesis inhibitor (pyrrolobenzodiazepine)
| Spectrum of activity: | Gram-negative |
| Details of activity: | Double stranded DNA cross linking agent; of the series of Spirogen pyrrolobenzodiazepines, this was the more potent against Gram positives |
| Institute where first reported: | Spirogen Ltd (Medimmune, USA) |
| Year first mentioned: | 2004 |
| Highest developmental phase: | Preclinical |
| Development status: | Inactive |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/substance/274591302 |
| Citation: |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.